Cart
sales@molnova.com
BMS-5
CAS No. 1338247-35-0
BMS-5( LIMKI-3 | LIMKI 3 | LIMKI3 | BMS-5 )
Catalog No. M17956 CAS No. 1338247-35-0
BMS-5 is a potent LIMK inhibitor with IC50s of 7 nM and 8 nM for LIMK1 and LIMK2, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 45 | In Stock |
|
| 5MG | 68 | In Stock |
|
| 10MG | 113 | In Stock |
|
| 25MG | 188 | In Stock |
|
| 50MG | 282 | In Stock |
|
| 100MG | 420 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
| 1 mL x 10 mM in DMSO | 80 | In Stock |
|
| 2MG | 48 | In Stock |
|
| 5MG | 72 | In Stock |
|
| 10MG | 119 | In Stock |
|
| 25MG | 199 | In Stock |
|
| 50MG | 291 | In Stock |
|
| 100MG | 434 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-5
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-5 is a potent LIMK inhibitor with IC50s of 7 nM and 8 nM for LIMK1 and LIMK2, respectively.
-
DescriptionLIMKI-3, also known as BMS-3, is a Potent LIM kinase inhibitor (IC50 values are 7 and 8 nM for LIMK1 and LIMK2 respectively). Inhibits cofilin phosphorylation in MDA-MB-231 breast cancer cells. Reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay.
-
In VitroBMS-5 (LIMKi 3) inhibits cofilin-Ser3 phosphorylation in a dose-dependent manner in Nf2ΔEx2 mouse Schwann cells (MSCs) with an IC50 of ~2 μM. BMS-5 (LIMKi 3) reduces Nf2ΔEx2 MSC viability in a dose-dependent manner with an IC50 of 3.9 μM, but does not significantly reduce the viability of control Nf2flox2/flox2 MSCs at equivalent BMS-5 concentrations. At 10 μM BMS-5, Nf2ΔEx2 MSC viability is 40% compared to 83% for controls.
-
In VivoBMS-5 (LIMKi 3) (20 or 200 μM/side) is bilaterally infused into the hippocampus of rats immediately after contextual fear conditioning training. Rats are tested for memory consolidation 48 h after fear conditioning. Post hoc analysis shows that the group treated with 200 μM BMS-5 express lower freezing levels compared to the 20 μM and vehicle groups (P<0.01).
-
SynonymsLIMKI-3 | LIMKI 3 | LIMKI3 | BMS-5
-
PathwayAngiogenesis
-
TargetPDGFR
-
RecptorLIMK1|LIMK2
-
Research AreaInflammation/Immunology|Neurological Disease
-
Indication——
Chemical Information
-
CAS Number1338247-35-0
-
Formula Weight431.29
-
Molecular FormulaC17H14Cl2F2N4OS
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 34 mg/mL; 78.83 mM
-
SMILESO=C(Nc1ncc(s1)c2cc(nn2c3c(Cl)cccc3Cl)C(F)F)C(C)C
-
Chemical NameN-[5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methylpropanamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ross-Macdonald P, et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther. 2008 Nov;7(11):3490-8.
molnova catalog
related products
-
SU16f
SU16f is a potent and selective PDGFRβ inhibitor (IC50s: 10 nM, 140 nM, 2.29 μM for PDGFRβ, PDGFR1, PDGFR2, respectively).
-
PDGFRα kinase inhibi...
PDGFRα kinase inhibitor 1 is a highly selective inhibitor of type II PDGFRα kinase (PDGFRα and PDGFRβ) with IC50 values of 132 nM and 6115 nM, respectively.
-
AG-1295
A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGFR kinase in vitro and in Swiss 3T3 cells with IC50 of 0.3-1 uM.
